Hjem › Tripelnegativ brystkreft
Kliniske studier for Tripelnegativ brystkreft rekrutterer i USA
147 studier for Tripelnegativ brystkreft rekrutterer deltakere på steder over hele USA.
Byer med flest studier
- Houston, TX42 studier
- New York City, NY31 studier
- Nashville, TN28 studier
- Los Angeles, CA27 studier
- Boston, MA26 studier
- San Antonio, TX23 studier
- St. Louis, MO21 studier
- Atlanta, GA20 studier
- Arlington, VA20 studier
- Dallas, TX18 studier
- Chicago, IL16 studier
- Columbus, OH16 studier
- Tampa, FL15 studier
- New Haven, CT15 studier
- Grand Rapids, MI15 studier
- Queens, NY15 studier
- Seattle, WA14 studier
- Austin, TX13 studier
- Philadelphia, PA13 studier
- West Valley City, UT13 studier
- San Diego, CA13 studier
- Durham, NC12 studier
- Orlando, FL12 studier
- Denver, CO12 studier
- Baltimore, MD12 studier
- Rochester, MN11 studier
- Washington, DC11 studier
- Pittsburgh, PA11 studier
- Edison, NJ11 studier
- Miami, FL11 studier
- San Francisco, CA11 studier
- Baldwin Park, CA10 studier
- Cleveland, OH10 studier
- Salt Lake City, UT9 studier
- Oklahoma City, OK9 studier
- Jacksonville, FL9 studier
- Detroit, MI9 studier
- Indianapolis, IN9 studier
- Aurora, CO9 studier
- Portland, OR9 studier
Etter delstat
- Alabama11 studier
- Arizona18 studier
- Arkansas3 studier
- California53 studier
- Colorado21 studier
- Connecticut19 studier
- Delaware3 studier
- District of Columbia7 studier
- Florida47 studier
- Georgia26 studier
- Illinois20 studier
- Indiana13 studier
- Iowa8 studier
- Kansas5 studier
- Kentucky6 studier
- Louisiana6 studier
- Maine3 studier
- Maryland18 studier
- Massachusetts26 studier
- Michigan28 studier
- Minnesota17 studier
- Missouri24 studier
- Nebraska6 studier
- Nevada6 studier
- New Jersey20 studier
- New Mexico3 studier
- New York46 studier
- North Carolina21 studier
- Ohio29 studier
- Oklahoma10 studier
- Oregon12 studier
- Pennsylvania23 studier
- Rhode Island4 studier
- South Carolina9 studier
- South Dakota7 studier
- Tennessee31 studier
- Texas59 studier
- Utah23 studier
- Virginia28 studier
- Washington20 studier
- Wisconsin7 studier
Nylig oppdaterte studier
Offisiell studietekst (engelsk)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekruttererFase 1/2
Alder 12 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT04585750A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06465069A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06270706Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
RekruttererObservasjonsstudie
Alder 18 til 120 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT07619534A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
RekruttererFase 1
Alder 19 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06586957177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07189871PRE-ISPY Phase I/II Oncology Platform Program
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT05868226Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT05422794First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 29. sep. 2026 · NCT06799065Study of AVZO-021 in Patients With Advanced Solid Tumors
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT05867251Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
Rekrutterer
Alder 30 og eldre · Kvinner · Oppdatert 25. sep. 2026 · NCT02945579A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06966700Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT04981119Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06393374A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06841354Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC
Rekrutterer
Alder 18 og eldre · Kvinner · Oppdatert 25. sep. 2026 · NCT07066189Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT05528133A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 24. sep. 2026 · NCT07229313Intratumoral N17350 in Advanced Solid Tumors
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 23. sep. 2026 · NCT07339176A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 23. sep. 2026 · NCT06618287Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 21. sep. 2026 · NCT05983432Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 18. sep. 2026 · NCT07340541A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 18. sep. 2026 · NCT07705334A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 17. sep. 2026 · NCT07020117Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 16. sep. 2026 · NCT06353997Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.